This morning, Mary Jo White (Chair of the SEC) addressed a meeting of the SEC Advisory Committee on Small and Emerging Companies and checklisted certain areas of SEC activity. In reference to the issue of whether “finders and other intermediaries” … Continue reading
Category Archives: The Law
Mainland China’s historic reputation of riding rough-shod over intellectual property rights seems, at least as to matters of form, something of the past. In a presentation to the Boston Bar Association on February 18th, a team of intellectual property attorneys … Continue reading
How do boards of directors function in larger, privately-held companies? The answer is: pretty much like boards of directors in publicly-held companies, according to a panel of directors convened February 9th in Boston by the National Association of Corporate Directors-New … Continue reading
Citrix has grown to a $3 billion company driven by approximately fifty acquisitions over the past decade since it went public, enjoying a comfortable 14% CAGR. Why did their senior vice president tell the January 14th Boston breakfast meeting of … Continue reading
Moving into the proxy season, what are the hottest board topics this year? Disclosure of corporate political contributions, the impact of enhanced SEC disclosure requirements on executive compensation, heightened audit committee responsibility, and board responsiveness to socially motivated activist shareholders, … Continue reading
Last week the SEC issued a staff report seeking reaction to proposed amendments to the definition of an “accredited investor.” Regulation D is the most relied-upon exemption from SEC (and typically State) registration requirements for the sale of securities, and … Continue reading
The SEC has been entertaining, for several years, a rule requiring reporting companies to disclose political contributions. Yesterday, a compromise budget bill was announced by Speaker Ryan which includes a rider barring the SEC from finalizing, issuing or implementing any … Continue reading
Dealing with the FDA today is getting slightly easier, but it is nothing to write home about. Agency plans will attempt to improve the regulatory experience; success remains to be demonstrated. Presentations by a research firm and by the Regional … Continue reading
Where is health care going in the United States? Well, no big surprises: it is costing more, is on an upwards cost trend given demographics (e.g. we are getting older as a population), and it is harder to get reimbursement. … Continue reading
At the December 9 symposium on FDA issues for medical device companies sponsored in Waltham by MassMEDIC (the association of device manufacturers), legislation passed by the House of Representatives that would greatly assist the industry was outlined, for the benefit … Continue reading